Yuan-yeh Kuo

TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification.

Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification.

Journal: Blood cancer journal

Published: May 24, 2026

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.

Journal: Blood research

Published: January 01, 2026

Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification.

Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification.

Journal: Blood cancer journal

Published: September 09, 2025

Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromes.

Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromes.

Journal: Blood research

Published: September 03, 2025

Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data.

Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data.

Journal: Blood cancer journal

Published: July 19, 2025

Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study.

Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 03, 2025

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.

Journal: Blood cancer journal

Published: February 13, 2025

Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends.

Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 25, 2024

Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems.

Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems.

Journal: Hematological oncology

Published: November 18, 2024

HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemia.

HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: September 02, 2024

IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo.

IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo.

Journal: EJHaem

Published: February 29, 2024

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Journal: Blood cancer journal

Published: December 23, 2023

Showing 1-12 of 60

Last Updated: 09/26/2026